Polyps are an end result of varying disease processes in the nasal cavities. Conditions leading to chronic inflammation in the nasal cavity such as bronchial asthma can lead to nasal polyps. The overall incidence of nasal polyps in children is 0.1%; the incidence in children with CF is 6-48%. Among adults, the incidence is 1-4% overall, with a range of 0.2-28%. Oral steroids are the most effective medical treatment for nasal polyposis.
In adults, most authors use prednisone (30-60 mg) for 4-7 days and taper the medicine for 1-3 weeks. Dosage varies for children, but the maximum dose is usually 1 mg/kg/d for 5-7 days, then taper over 1-3 weeks. Based on current data, the evidence for efficacy of available anti-IgE and anti-IL-5 antibodies on the market is very low, and more studies are needed in order to recommend their use in the treatment of CRSwNP patients.